Jane Goodall
YOU?
Author Swipe
View article: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer Open
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects. However, mechanisms underlying PARPi resistance are not fully understood. While acquire…
View article: Stop elephant hunting in Tanzania borderlands
Stop elephant hunting in Tanzania borderlands Open
1,2721MetricsTotal Downloads1,272Last 6 Months1,035Last 12 Months1,272Total Citations1Last 6 Months1Last 12 Months1View all metrics
View article: Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Consort diagram describing samples disposition in the study.
View article: Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with…
View article: Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Consort diagram describing samples disposition in the study.
View article: Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Summary of tumor (baseline) and cfDNA (baseline and progression) mutations detected by WES for a patient who responded to Olaparib. New events in TP53 and TSC2 were detected at progression.
View article: Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Plots showing percentage changes in total cfDNA concentration for each patient at weeks 4 and 8 of treatment, compared to same-patient baseline value. The left plot includes non-responding patients and the right plot includes patients who …
View article: Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Summary of tumor (baseline) and cfDNA (baseline and progression) mutations detected by WES for a patient who responded to Olaparib. New events in TP53 and TSC2 were detected at progression.
View article: Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Plots showing percentage changes in total cfDNA concentration for each patient at weeks 4 and 8 of treatment, compared to same-patient baseline value. The left plot includes non-responding patients and the right plot includes patients who …
View article: Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with…
View article: Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Baseline values at start of abiraterone
View article: Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Sample overview
View article: Figure S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Figure S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Clinical data: a) Summary of prior treatments of all 14 patients prior to apheresis. b) A histogram presenting the lymphocyte and neutrophil counts (x109/L) in peripheral blood pre- and post-apheresis procedures.
View article: Data from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Data from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Purpose: CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and assessed the molec…
View article: Supplementary Figure 3 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Figure 3 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Combined SPOP/ CHD1 status and time/ response to abiraterone.
View article: Table S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Table S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Summary of individual CTCs per patient with percentage of the genome covered by a copy number segment and percentage of genes that are altered.
View article: Figure S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Figure S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Clinical data: a) Summary of prior treatments of all 14 patients prior to apheresis. b) A histogram presenting the lymphocyte and neutrophil counts (x109/L) in peripheral blood pre- and post-apheresis procedures.
View article: Data from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Data from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration Open
Purpose: We evaluated whether next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) could be used for patient selection and as a tumor clone response biomarker in patients with advanced cancers participating in early-phase …
View article: Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Baseline values at start of abiraterone
View article: Supplementary Table 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Table 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
SPOP mutation identified in this cohort.
View article: Supplementary Data 6 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Supplementary Data 6 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration Open
Supplementary Data 6: Monitoring of somatic genomic alterations in plasma during targeted therapy. Allele frequencies (AF) of identified mutations are represented on the left Y-axis while the sum of the target lesions on the CT scan, are r…
View article: Supplementary Figure 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Figure 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Additional Information on molecular analyses determining CHD1 and SPOP status
View article: Figure S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Figure S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Unsupervised clustering analyses of all samples: Fan presentation of unsupervised clustering of all CTCs, tissue biopsies and organoids evaluated in this study. Each CTC is annotated as a circle, each tissue sample as a square, and an orga…
View article: supplementary Data 1-7 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
supplementary Data 1-7 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration Open
Supplementary Data 1: Primers and probes for ddPCR assay Supplementary Data 2: Consort Diagram Supplementary Data 3: List of drugs Supplementary Data 4: Cross validation of PGM sequencing assay with ddPCR Supplementary Data 5: To test intr…
View article: Data from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Data from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from meta…
View article: Table S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Table S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Baseline characteristics of study patients (n=14). *All values given are at time of apheresis unless otherwise specified. â^§The Eastern Cooperative Oncology Group (ECOG) performance status score ranges from 0 to 5, with 0 indicating no sy…
View article: Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Summary of the CTC and WBC counts from both peripheral blood and apheresis product for all 14 patients, with additional clinical characteristics including sites of disease at apheresis and time to disease progression following apheresis pr…
View article: Table S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Table S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Summary of individual CTCs per patient with percentage of the genome covered by a copy number segment and percentage of genes that are altered.
View article: Figure S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Figure S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis Open
Summary of the validation steps. a) Male vs female: Genome plot of amplified male DNA vs amplified female DNA using the Ampli 1 kit. b) WBC vs WBC: Genomic profile of Ampli1 amplified WBCs against another WBC. c) Dilution evaluation: Genom…